Learning Objectives:

  1. Discuss current approved hematologic CAR-T cell therapies and considerations in terms of treatment sequencing pre- and post-CAR-T, management of side effects, and harnessing community resources to ensure appropriate community oncology referral and collaboration.


  1. Explore the landscape of phase I trials of T cell therapy in solid tumors, including examples of appropriate patients to consider for referral and ways to co-manage with community providers.


  1. Consider the roles of other immunologic therapies in the context of above T-cell therapies, such as oncolytic viral therapy in melanoma, or bispecific T cell engagers/antigen drug conjugates in hematologic malignancies.


Session date: 
10/26/2021 - 7:00am to 8:00am CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Mariam Nawas, MD & Daniel Olson MD